Trifarotene cream

DRUG4 trials

Sponsors

Galderma R&D, Kafrelsheikh University

Conditions

Acne VulgarisSkin and Connective Tissue Diseases

Phase 4

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)

CompletedNCT04451330

Galderma R&DAcne Vulgaris

Start: 2020-07-29End: 2021-04-26Updated: 2022-05-10

Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation

CompletedNCT04856904

Galderma R&DAcne Vulgaris

Start: 2021-05-28End: 2023-06-30Updated: 2024-06-11

AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation

CompletedNCT05089708

Galderma R&DAcne Vulgaris

Start: 2021-12-22End: 2022-12-15Updated: 2023-12-20

Unknown Phase

Trifarotene 0.005% Cream: A Novel Topical Retinoid as a Monotherapy in Mild to Moderate Facial Acne Vulgaris in Egyptian patients

Active, not recruitingPACTR202510658002240

Kafrelsheikh UniversitySkin and Connective Tissue Diseases

Start: 2024-12-01Target: 20Updated: 2026-09-14

Related Papers

Patient Insights on Acne Hyperpigmentation, Trifarotene, and Skincare: 6-Month, LEAP Phase 4 Qualitative Exit Interview Findings.

2025-11-24

Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study.

2023-10-1511 citations